Company: CORT
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001628280-25-019942
Chunk: 39

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 39
---
PCAOB).

In this context and in connection with the audited financial statements contained in the Company’s Annual Report on Form 10-K, the Audit Committee:

• reviewed and discussed the audited financial statements as of and for the fiscal year ended December 31, 2024 with the Company’s management and Ernst & Young LLP, the Company’s independent registered public accounting firm;

• discussed with Ernst & Young LLP the matters required to be discussed by the applicable requirements of the PCAOB and the SEC;

• received the written disclosures and the letter from Ernst & Young LLP required by applicable requirements of the PCAOB regarding Ernst & Young LLP’s communications with the Audit Committee concerning independence and discussed with Ernst & Young LLP their independence;

• considered and discussed whether the non-audit services, if any, performed by Ernst & Young LLP are compatible with maintaining their independence;

• reviewed and discussed the reports of management and Ernst & Young LLP on their assessments of the effectiveness of the Company’s internal control over financial reporting as of the end of the most recent fiscal year;

• reviewed the disclosures regarding the Company’s system of internal controls required to be contained in the Company’s Form 10-K;

• based on the foregoing reviews and discussions, recommended to the Board that the audited financial statements and management’s report on the effectiveness of the Company’s internal control over financial reporting as of December 31, 2024 be included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the SEC; and

• instructed Ernst & Young LLP that the Audit Committee expects to be advised if there are any subjects that require special attention.

The Audit Committee has also recommended in Proposal No. 2 in this Proxy Statement the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.

| Audit Committee          |
| Gregg Alton, Chairman    |
| Gillian M. Cannon, Ph.D. |
| David L. Mahoney         |
| Joshua M. Murray         |

| * |     | The material in this report is not soliciting material, and is not deemed filed with the SEC. |

<div align='center'>32</div>

### FEES OF THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Fees Incurred by Corcept for Ernst & Young LLP

The following table shows the fees paid or accrued by Corcept for audit and other services provided by Ernst & Young LLP, our independent registered